NCT05899621View on ClinicalTrials.gov

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

RecruitingOBSERVATIONAL
Enrollment

332

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Follicular Lymphoma
Interventions
DRUG

Obinutuzumab

Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Lenalidomide

Lenalidomide PO will be administered as per the schedule specified in the respective arm.

DRUG

Bendamustine

Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Cyclophosphamide

Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Doxorubicin

Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Vincristine

Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Prednisone

Prednisone PO will be administered as per the schedule specified in the respective arm.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER